Industry Research Reports

Home > Reports > Medical Care > Cancer Tumor Profiling - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Cancer Tumor Profiling - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 129 Pages

Report ld: 2332879

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.

The global market for Cancer Tumor Profiling was estimated to be worth US$ 39410 million in 2023 and is forecast to a readjusted size of US$ 81350 million by 2030 with a CAGR of 10.4% during the forecast period 2024-2030

Cancer Tumor Profiling Market Size(US$)

M= millions and B=billions

The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Tumor Profiling, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Tumor Profiling by region & country, by Type, and by Application.

The Cancer Tumor Profiling market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Tumor Profiling.

Market Segmentation

Report Metric
Details
Report Title
Cancer Tumor Profiling - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 81350 million
CAGR(2024-2030)
10.4%
Market Size Available for Years
2019-2030
Global Cancer Tumor Profiling Companies Covered
Qiagen N.V., Roche Molecular Systems Inc., Abott Molecular, Illumina Inc., NeoGenomics Laboratories, HTG Molecular Diagnostic, Genomic Health Inc., Hologic Gen-Probe, BD Biosciences, Siemens Healthineers, Claris Life Sciences, Personal Genome Diagnostics, Inc., Perthera, Inc., Foundation Medicine, Inc, V., Strand, ApoCell, Contextual Genomics, Agendia, GenScript
Global Cancer Tumor Profiling Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Tumor Profiling Market, Segment by Type
Next-generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In Situ Hybridization (ISH)

Microarray

Others
Global Cancer Tumor Profiling Market, Segment by Application
Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Research Applications
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Tumor Profiling manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Tumor Profiling in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Tumor Profiling in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Cancer Tumor Profiling Product Introduction
    1.2 Global Cancer Tumor Profiling Market Size Forecast
    1.3 Cancer Tumor Profiling Market Trends & Drivers
        1.3.1 Cancer Tumor Profiling Industry Trends
        1.3.2 Cancer Tumor Profiling Market Drivers & Opportunity
        1.3.3 Cancer Tumor Profiling Market Challenges
        1.3.4 Cancer Tumor Profiling Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Cancer Tumor Profiling Players Revenue Ranking (2023)
    2.2 Global Cancer Tumor Profiling Revenue by Company (2019-2024)
    2.3 Key Companies Cancer Tumor Profiling Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Cancer Tumor Profiling Product Offered
    2.5 Key Companies Time to Begin Mass Production of Cancer Tumor Profiling
    2.6 Cancer Tumor Profiling Market Competitive Analysis
        2.6.1 Cancer Tumor Profiling Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Cancer Tumor Profiling Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Tumor Profiling as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Next-generation Sequencing (NGS)
        3.1.2 Polymerase Chain Reaction (PCR)
        3.1.3 Immunohistochemistry (IHC)
        3.1.4 In Situ Hybridization (ISH)
        3.1.5 Microarray
        3.1.6 Others
    3.2 Global Cancer Tumor Profiling Sales Value by Type
        3.2.1 Global Cancer Tumor Profiling Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Cancer Tumor Profiling Sales Value, by Type (2019-2030)
        3.2.3 Global Cancer Tumor Profiling Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Personalized Medicine
        4.1.2 Diagnostics
        4.1.3 Biomarker Discovery
        4.1.4 Prognostics
        4.1.5 Research Applications
    4.2 Global Cancer Tumor Profiling Sales Value by Application
        4.2.1 Global Cancer Tumor Profiling Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Cancer Tumor Profiling Sales Value, by Application (2019-2030)
        4.2.3 Global Cancer Tumor Profiling Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Cancer Tumor Profiling Sales Value by Region
        5.1.1 Global Cancer Tumor Profiling Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Cancer Tumor Profiling Sales Value by Region (2019-2024)
        5.1.3 Global Cancer Tumor Profiling Sales Value by Region (2025-2030)
        5.1.4 Global Cancer Tumor Profiling Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Cancer Tumor Profiling Sales Value, 2019-2030
        5.2.2 North America Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Cancer Tumor Profiling Sales Value, 2019-2030
        5.3.2 Europe Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Cancer Tumor Profiling Sales Value, 2019-2030
        5.4.2 Asia Pacific Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Cancer Tumor Profiling Sales Value, 2019-2030
        5.5.2 South America Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Cancer Tumor Profiling Sales Value, 2019-2030
        5.6.2 Middle East & Africa Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Cancer Tumor Profiling Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Cancer Tumor Profiling Sales Value
    6.3 United States
        6.3.1 United States Cancer Tumor Profiling Sales Value, 2019-2030
        6.3.2 United States Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Cancer Tumor Profiling Sales Value, 2019-2030
        6.4.2 Europe Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Cancer Tumor Profiling Sales Value, 2019-2030
        6.5.2 China Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Cancer Tumor Profiling Sales Value, 2019-2030
        6.6.2 Japan Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Cancer Tumor Profiling Sales Value, 2019-2030
        6.7.2 South Korea Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Cancer Tumor Profiling Sales Value, 2019-2030
        6.8.2 Southeast Asia Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Cancer Tumor Profiling Sales Value, 2019-2030
        6.9.2 India Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Cancer Tumor Profiling Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Qiagen N.V.
        7.1.1 Qiagen N.V. Profile
        7.1.2 Qiagen N.V. Main Business
        7.1.3 Qiagen N.V. Cancer Tumor Profiling Products, Services and Solutions
        7.1.4 Qiagen N.V. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.1.5 Qiagen N.V. Recent Developments
    7.2 Roche Molecular Systems Inc.
        7.2.1 Roche Molecular Systems Inc. Profile
        7.2.2 Roche Molecular Systems Inc. Main Business
        7.2.3 Roche Molecular Systems Inc. Cancer Tumor Profiling Products, Services and Solutions
        7.2.4 Roche Molecular Systems Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.2.5 Roche Molecular Systems Inc. Recent Developments
    7.3 Abott Molecular
        7.3.1 Abott Molecular Profile
        7.3.2 Abott Molecular Main Business
        7.3.3 Abott Molecular Cancer Tumor Profiling Products, Services and Solutions
        7.3.4 Abott Molecular Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.3.5 Illumina Inc. Recent Developments
    7.4 Illumina Inc.
        7.4.1 Illumina Inc. Profile
        7.4.2 Illumina Inc. Main Business
        7.4.3 Illumina Inc. Cancer Tumor Profiling Products, Services and Solutions
        7.4.4 Illumina Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.4.5 Illumina Inc. Recent Developments
    7.5 NeoGenomics Laboratories
        7.5.1 NeoGenomics Laboratories Profile
        7.5.2 NeoGenomics Laboratories Main Business
        7.5.3 NeoGenomics Laboratories Cancer Tumor Profiling Products, Services and Solutions
        7.5.4 NeoGenomics Laboratories Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.5.5 NeoGenomics Laboratories Recent Developments
    7.6 HTG Molecular Diagnostic
        7.6.1 HTG Molecular Diagnostic Profile
        7.6.2 HTG Molecular Diagnostic Main Business
        7.6.3 HTG Molecular Diagnostic Cancer Tumor Profiling Products, Services and Solutions
        7.6.4 HTG Molecular Diagnostic Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.6.5 HTG Molecular Diagnostic Recent Developments
    7.7 Genomic Health Inc.
        7.7.1 Genomic Health Inc. Profile
        7.7.2 Genomic Health Inc. Main Business
        7.7.3 Genomic Health Inc. Cancer Tumor Profiling Products, Services and Solutions
        7.7.4 Genomic Health Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.7.5 Genomic Health Inc. Recent Developments
    7.8 Hologic Gen-Probe
        7.8.1 Hologic Gen-Probe Profile
        7.8.2 Hologic Gen-Probe Main Business
        7.8.3 Hologic Gen-Probe Cancer Tumor Profiling Products, Services and Solutions
        7.8.4 Hologic Gen-Probe Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.8.5 Hologic Gen-Probe Recent Developments
    7.9 BD Biosciences
        7.9.1 BD Biosciences Profile
        7.9.2 BD Biosciences Main Business
        7.9.3 BD Biosciences Cancer Tumor Profiling Products, Services and Solutions
        7.9.4 BD Biosciences Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.9.5 BD Biosciences Recent Developments
    7.10 Siemens Healthineers
        7.10.1 Siemens Healthineers Profile
        7.10.2 Siemens Healthineers Main Business
        7.10.3 Siemens Healthineers Cancer Tumor Profiling Products, Services and Solutions
        7.10.4 Siemens Healthineers Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.10.5 Siemens Healthineers Recent Developments
    7.11 Claris Life Sciences
        7.11.1 Claris Life Sciences Profile
        7.11.2 Claris Life Sciences Main Business
        7.11.3 Claris Life Sciences Cancer Tumor Profiling Products, Services and Solutions
        7.11.4 Claris Life Sciences Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.11.5 Claris Life Sciences Recent Developments
    7.12 Personal Genome Diagnostics, Inc.
        7.12.1 Personal Genome Diagnostics, Inc. Profile
        7.12.2 Personal Genome Diagnostics, Inc. Main Business
        7.12.3 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Products, Services and Solutions
        7.12.4 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.12.5 Personal Genome Diagnostics, Inc. Recent Developments
    7.13 Perthera, Inc.
        7.13.1 Perthera, Inc. Profile
        7.13.2 Perthera, Inc. Main Business
        7.13.3 Perthera, Inc. Cancer Tumor Profiling Products, Services and Solutions
        7.13.4 Perthera, Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.13.5 Perthera, Inc. Recent Developments
    7.14 Foundation Medicine, Inc
        7.14.1 Foundation Medicine, Inc Profile
        7.14.2 Foundation Medicine, Inc Main Business
        7.14.3 Foundation Medicine, Inc Cancer Tumor Profiling Products, Services and Solutions
        7.14.4 Foundation Medicine, Inc Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.14.5 Foundation Medicine, Inc Recent Developments
    7.15 V., Strand
        7.15.1 V., Strand Profile
        7.15.2 V., Strand Main Business
        7.15.3 V., Strand Cancer Tumor Profiling Products, Services and Solutions
        7.15.4 V., Strand Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.15.5 V., Strand Recent Developments
    7.16 ApoCell
        7.16.1 ApoCell Profile
        7.16.2 ApoCell Main Business
        7.16.3 ApoCell Cancer Tumor Profiling Products, Services and Solutions
        7.16.4 ApoCell Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.16.5 ApoCell Recent Developments
    7.17 Contextual Genomics
        7.17.1 Contextual Genomics Profile
        7.17.2 Contextual Genomics Main Business
        7.17.3 Contextual Genomics Cancer Tumor Profiling Products, Services and Solutions
        7.17.4 Contextual Genomics Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.17.5 Contextual Genomics Recent Developments
    7.18 Agendia
        7.18.1 Agendia Profile
        7.18.2 Agendia Main Business
        7.18.3 Agendia Cancer Tumor Profiling Products, Services and Solutions
        7.18.4 Agendia Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.18.5 Agendia Recent Developments
    7.19 GenScript
        7.19.1 GenScript Profile
        7.19.2 GenScript Main Business
        7.19.3 GenScript Cancer Tumor Profiling Products, Services and Solutions
        7.19.4 GenScript Cancer Tumor Profiling Revenue (US$ Million) & (2019-2024)
        7.19.5 GenScript Recent Developments

 8 Industry Chain Analysis
    8.1 Cancer Tumor Profiling Industrial Chain
    8.2 Cancer Tumor Profiling Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Cancer Tumor Profiling Sales Model
        8.5.2 Sales Channel
        8.5.3 Cancer Tumor Profiling Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Cancer Tumor Profiling Market Trends
    Table 2. Cancer Tumor Profiling Market Drivers & Opportunity
    Table 3. Cancer Tumor Profiling Market Challenges
    Table 4. Cancer Tumor Profiling Market Restraints
    Table 5. Global Cancer Tumor Profiling Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Tumor Profiling Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Cancer Tumor Profiling Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Cancer Tumor Profiling Product Type
    Table 9. Key Companies Time to Begin Mass Production of Cancer Tumor Profiling
    Table 10. Global Cancer Tumor Profiling Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Tumor Profiling as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Cancer Tumor Profiling Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Cancer Tumor Profiling Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Cancer Tumor Profiling Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Cancer Tumor Profiling Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Cancer Tumor Profiling Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Cancer Tumor Profiling Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Cancer Tumor Profiling Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Cancer Tumor Profiling Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Cancer Tumor Profiling Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Cancer Tumor Profiling Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Cancer Tumor Profiling Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Cancer Tumor Profiling Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Cancer Tumor Profiling Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Cancer Tumor Profiling Sales Value by Region (2019-2024) & (%)
    Table 27. Global Cancer Tumor Profiling Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Cancer Tumor Profiling Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Cancer Tumor Profiling Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Cancer Tumor Profiling Sales Value, (2025-2030) & (US$ Million)
    Table 31. Qiagen N.V. Basic Information List
    Table 32. Qiagen N.V. Description and Business Overview
    Table 33. Qiagen N.V. Cancer Tumor Profiling Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Cancer Tumor Profiling Business of Qiagen N.V. (2019-2024)
    Table 35. Qiagen N.V. Recent Developments
    Table 36. Roche Molecular Systems Inc. Basic Information List
    Table 37. Roche Molecular Systems Inc. Description and Business Overview
    Table 38. Roche Molecular Systems Inc. Cancer Tumor Profiling Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Cancer Tumor Profiling Business of Roche Molecular Systems Inc. (2019-2024)
    Table 40. Roche Molecular Systems Inc. Recent Developments
    Table 41. Abott Molecular Basic Information List
    Table 42. Abott Molecular Description and Business Overview
    Table 43. Abott Molecular Cancer Tumor Profiling Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Cancer Tumor Profiling Business of Abott Molecular (2019-2024)
    Table 45. Abott Molecular Recent Developments
    Table 46. Illumina Inc. Basic Information List
    Table 47. Illumina Inc. Description and Business Overview
    Table 48. Illumina Inc. Cancer Tumor Profiling Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Cancer Tumor Profiling Business of Illumina Inc. (2019-2024)
    Table 50. Illumina Inc. Recent Developments
    Table 51. NeoGenomics Laboratories Basic Information List
    Table 52. NeoGenomics Laboratories Description and Business Overview
    Table 53. NeoGenomics Laboratories Cancer Tumor Profiling Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Cancer Tumor Profiling Business of NeoGenomics Laboratories (2019-2024)
    Table 55. NeoGenomics Laboratories Recent Developments
    Table 56. HTG Molecular Diagnostic Basic Information List
    Table 57. HTG Molecular Diagnostic Description and Business Overview
    Table 58. HTG Molecular Diagnostic Cancer Tumor Profiling Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Cancer Tumor Profiling Business of HTG Molecular Diagnostic (2019-2024)
    Table 60. HTG Molecular Diagnostic Recent Developments
    Table 61. Genomic Health Inc. Basic Information List
    Table 62. Genomic Health Inc. Description and Business Overview
    Table 63. Genomic Health Inc. Cancer Tumor Profiling Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Cancer Tumor Profiling Business of Genomic Health Inc. (2019-2024)
    Table 65. Genomic Health Inc. Recent Developments
    Table 66. Hologic Gen-Probe Basic Information List
    Table 67. Hologic Gen-Probe Description and Business Overview
    Table 68. Hologic Gen-Probe Cancer Tumor Profiling Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Cancer Tumor Profiling Business of Hologic Gen-Probe (2019-2024)
    Table 70. Hologic Gen-Probe Recent Developments
    Table 71. BD Biosciences Basic Information List
    Table 72. BD Biosciences Description and Business Overview
    Table 73. BD Biosciences Cancer Tumor Profiling Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Cancer Tumor Profiling Business of BD Biosciences (2019-2024)
    Table 75. BD Biosciences Recent Developments
    Table 76. Siemens Healthineers Basic Information List
    Table 77. Siemens Healthineers Description and Business Overview
    Table 78. Siemens Healthineers Cancer Tumor Profiling Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Cancer Tumor Profiling Business of Siemens Healthineers (2019-2024)
    Table 80. Siemens Healthineers Recent Developments
    Table 81. Claris Life Sciences Basic Information List
    Table 82. Claris Life Sciences Description and Business Overview
    Table 83. Claris Life Sciences Cancer Tumor Profiling Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Cancer Tumor Profiling Business of Claris Life Sciences (2019-2024)
    Table 85. Claris Life Sciences Recent Developments
    Table 86. Personal Genome Diagnostics, Inc. Basic Information List
    Table 87. Personal Genome Diagnostics, Inc. Description and Business Overview
    Table 88. Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Cancer Tumor Profiling Business of Personal Genome Diagnostics, Inc. (2019-2024)
    Table 90. Personal Genome Diagnostics, Inc. Recent Developments
    Table 91. Perthera, Inc. Basic Information List
    Table 92. Perthera, Inc. Description and Business Overview
    Table 93. Perthera, Inc. Cancer Tumor Profiling Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Cancer Tumor Profiling Business of Perthera, Inc. (2019-2024)
    Table 95. Perthera, Inc. Recent Developments
    Table 96. Foundation Medicine, Inc Basic Information List
    Table 97. Foundation Medicine, Inc Description and Business Overview
    Table 98. Foundation Medicine, Inc Cancer Tumor Profiling Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Cancer Tumor Profiling Business of Foundation Medicine, Inc (2019-2024)
    Table 100. Foundation Medicine, Inc Recent Developments
    Table 101. V., Strand Basic Information List
    Table 102. V., Strand Description and Business Overview
    Table 103. V., Strand Cancer Tumor Profiling Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Cancer Tumor Profiling Business of V., Strand (2019-2024)
    Table 105. V., Strand Recent Developments
    Table 106. ApoCell Basic Information List
    Table 107. ApoCell Description and Business Overview
    Table 108. ApoCell Cancer Tumor Profiling Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Cancer Tumor Profiling Business of ApoCell (2019-2024)
    Table 110. ApoCell Recent Developments
    Table 111. Contextual Genomics Basic Information List
    Table 112. Contextual Genomics Description and Business Overview
    Table 113. Contextual Genomics Cancer Tumor Profiling Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Cancer Tumor Profiling Business of Contextual Genomics (2019-2024)
    Table 115. Contextual Genomics Recent Developments
    Table 116. Agendia Basic Information List
    Table 117. Agendia Description and Business Overview
    Table 118. Agendia Cancer Tumor Profiling Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Cancer Tumor Profiling Business of Agendia (2019-2024)
    Table 120. Agendia Recent Developments
    Table 121. GenScript Basic Information List
    Table 122. GenScript Description and Business Overview
    Table 123. GenScript Cancer Tumor Profiling Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Cancer Tumor Profiling Business of GenScript (2019-2024)
    Table 125. GenScript Recent Developments
    Table 126. Key Raw Materials Lists
    Table 127. Raw Materials Key Suppliers Lists
    Table 128. Cancer Tumor Profiling Downstream Customers
    Table 129. Cancer Tumor Profiling Distributors List
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
    Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Cancer Tumor Profiling Product Picture
    Figure 2. Global Cancer Tumor Profiling Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 4. Cancer Tumor Profiling Report Years Considered
    Figure 5. Global Cancer Tumor Profiling Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Tumor Profiling Revenue in 2023
    Figure 7. Cancer Tumor Profiling Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Next-generation Sequencing (NGS) Picture
    Figure 9. Polymerase Chain Reaction (PCR) Picture
    Figure 10. Immunohistochemistry (IHC) Picture
    Figure 11. In Situ Hybridization (ISH) Picture
    Figure 12. Microarray Picture
    Figure 13. Others Picture
    Figure 14. Global Cancer Tumor Profiling Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Cancer Tumor Profiling Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Product Picture of Personalized Medicine
    Figure 17. Product Picture of Diagnostics
    Figure 18. Product Picture of Biomarker Discovery
    Figure 19. Product Picture of Prognostics
    Figure 20. Product Picture of Research Applications
    Figure 21. Global Cancer Tumor Profiling Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 22. Global Cancer Tumor Profiling Sales Value Market Share by Application, 2023 & 2030
    Figure 23. North America Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 24. North America Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    Figure 25. Europe Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 26. Europe Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    Figure 27. Asia Pacific Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 28. Asia Pacific Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    Figure 29. South America Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 30. South America Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    Figure 31. Middle East & Africa Cancer Tumor Profiling Sales Value (2019-2030) & (US$ Million)
    Figure 32. Middle East & Africa Cancer Tumor Profiling Sales Value by Country (%), 2023 VS 2030
    Figure 33. Key Countries/Regions Cancer Tumor Profiling Sales Value (%), (2019-2030)
    Figure 34. United States Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 35. United States Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 36. United States Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 37. Europe Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Europe Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 39. Europe Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 40. China Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 41. China Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 42. China Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 43. Japan Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Japan Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 45. Japan Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 46. South Korea Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 47. South Korea Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 48. South Korea Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 49. Southeast Asia Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 50. Southeast Asia Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 51. Southeast Asia Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 52. India Cancer Tumor Profiling Sales Value, (2019-2030) & (US$ Million)
    Figure 53. India Cancer Tumor Profiling Sales Value by Type (%), 2023 VS 2030
    Figure 54. India Cancer Tumor Profiling Sales Value by Application (%), 2023 VS 2030
    Figure 55. Cancer Tumor Profiling Industrial Chain
    Figure 56. Cancer Tumor Profiling Manufacturing Cost Structure
    Figure 57. Channels of Distribution (Direct Sales, and Distribution)
    Figure 58. Bottom-up and Top-down Approaches for This Report
    Figure 59. Data Triangulation

Description

Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.

The global market for Cancer Tumor Profiling was estimated to be worth US$ 39410 million in 2023 and is forecast to a readjusted size of US$ 81350 million by 2030 with a CAGR of 10.4% during the forecast period 2024-2030

The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Tumor Profiling, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Tumor Profiling by region & country, by Type, and by Application.

The Cancer Tumor Profiling market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Tumor Profiling.

Market Segmentation